RMC-4630 is under clinical development by Revolution Medicines and currently in Phase I for Central Nervous System (CNS) Cancer. According to GlobalData, Phase I drugs for Central Nervous System (CNS) Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RMC-4630’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RMC-4630 overview
RMC-4630 is under development for the treatment of relapsed/refractory solid tumors including advanced colorectal cancer, breast cancer, non small cell lung cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, neuroendocrine/carcinoid cancer, gastroesophageal junction carcinoma, gallbladder/biliary cancer, lip cancer, oral cavity and pharynx, esophageal cancer, stomach cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, liver cancer, other digestive organ, laryngeal cancer, bones and joints, soft tissue sarcoma, mycosis fungoides, cervical cancer, corpus uteri, ovarian cancer, prostate cancer, urinary bladder cancer, kidney cancer, brain cancer and nervous system, thyroid cancer, unknown sites, other endocrine system, Kaposi sarcoma, melanoma and skin cancer. It is administered through oral route. The drug candidate acts by targeting SHP2. It is developed based on breakthrough modular synthesis technology.
Revolution Medicines overview
Revolution Medicines is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
For a complete picture of RMC-4630’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
